Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival.
biologic failure
biologic persistence
biologic survival
multi-biologic use
psoriasis
Journal
Journal of psoriasis and psoriatic arthritis
ISSN: 2475-5311
Titre abrégé: J Psoriasis Psoriatic Arthritis
Pays: United States
ID NLM: 101695066
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
medline:
1
1
2023
pubmed:
1
1
2023
entrez:
19
9
2024
Statut:
ppublish
Résumé
Despite their impressive efficacy in phase 3 trials, biologic agents for psoriasis (PsO) may lose efficacy over time. The factors associated with loss of efficacy have yet to be fully elucidated. We aimed to identify factors associated with PsO patients using multiple biologics in comparison to patients who used 1 biologic. We also reviewed the literature comparing the survival of different biologic agents for PsO. We examined clinical data from 222 psoriasis patients at the University of California San Francisco, of whom 51 reported use of 3 or more biologics and of whom 171 reported use of only a single biologic agent at the time of enrollment into a research database from 2006-2020. In univariate analysis, duration of PsO, initial presentation of PsO on the gluteal cleft, erythrodermic psoriasis, and acne were associated with using 3 or more biologics. In multivariate analysis, duration of PsO, erythrodermic psoriasis, and acne remained significant. Our review of biologic survival revealed differences according to biologic class. We identified novel factors associated with multi-biologic use in PsO. Further studies in this area are needed to achieve a precision medicine approach.
Sections du résumé
Background
UNASSIGNED
Despite their impressive efficacy in phase 3 trials, biologic agents for psoriasis (PsO) may lose efficacy over time. The factors associated with loss of efficacy have yet to be fully elucidated.
Objective
UNASSIGNED
We aimed to identify factors associated with PsO patients using multiple biologics in comparison to patients who used 1 biologic. We also reviewed the literature comparing the survival of different biologic agents for PsO.
Methods
UNASSIGNED
We examined clinical data from 222 psoriasis patients at the University of California San Francisco, of whom 51 reported use of 3 or more biologics and of whom 171 reported use of only a single biologic agent at the time of enrollment into a research database from 2006-2020.
Results
UNASSIGNED
In univariate analysis, duration of PsO, initial presentation of PsO on the gluteal cleft, erythrodermic psoriasis, and acne were associated with using 3 or more biologics. In multivariate analysis, duration of PsO, erythrodermic psoriasis, and acne remained significant. Our review of biologic survival revealed differences according to biologic class.
Conclusion
UNASSIGNED
We identified novel factors associated with multi-biologic use in PsO. Further studies in this area are needed to achieve a precision medicine approach.
Identifiants
pubmed: 39296952
doi: 10.1177/24755303221131259
pii: 10.1177_24755303221131259
pmc: PMC11361481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-18Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Elizabeth Wallace serves as a research investigator for Argenx, Pfizer, and Target RWE. Jose Scher has received research funding from UCB, Janssen, Abbvie, Pfizer, Novartis, Sanofi, and BMS. Tina Bhutani has received research funding from Abbvie, Celgene, Galderma, Janssen, Pfizer, Regeneron, and Sun. She has served as an advisor for Abbvie, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Leo, Lilly, and Novartis. April W. Armstrong serves as a research investigator and/or scientific advisor to AbbVie, BMS, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed. George Gondo is an employee of the National Psoriasis Foundation. Stacie Bell is a former employee of the National Psoriasis Foundation. Wilson Liao has received research grant funding from Abbvie, Amgen, Janssen, Leo, Novartis, Pfizer, Regeneron, and TRex Bio.